McKesson Corporation logo

McKesson Corporation

MCK

NYSEHealthcareMedical - Distribution

Latest quote

$859.69

+$20.15 · +2.40%

Aug 21, 3:55 PM ET

MCK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

75

Undervalued

Momentum

47

Neutral

Sentiment

63

Bullish

Risk resilience

78

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
US
CEO
Brian S. Tyler
Listed since
Nov 10, 1994
Employees
42,300

Market position

Volume
835.85K
0.75× average
Average volume
1.11M
Average daily volume
Market cap
100.56B USD
Beta
0.31
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
111.6B USD
P/E (TTM)
22.89×
P/B (TTM)
-24.05×
P/S (TTM)
0.24×
EV / EBITDA
15.55×
Earnings yield
4.45%
Free cash flow yield
5.06%
Dividend yield
0.38%

Profitability & efficiency

Gross margin
3.64%
Operating margin
1.62%
Net margin
1.12%
Return on equity
-219.24%
Return on assets
5.78%
Return on invested capital
31.48%

Financial health

Debt / equity
-2.76×
Current ratio
0.85×
Altman Z-score
5.81
Piotroski F-score
7 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends5%3%2%-0%Gross margin, FY2022: 4.79%Gross margin, FY2023: 4.29%Gross margin, FY2024: 3.95%Gross margin, FY2025: 3.48%Gross margin, FY2026: 3.61%Operating margin, FY2022: 1.03%Operating margin, FY2023: 1.61%Operating margin, FY2024: 1.27%Operating margin, FY2025: 1.22%Operating margin, FY2026: 1.60%Net margin, FY2022: 0.42%Net margin, FY2023: 1.29%Net margin, FY2024: 0.97%Net margin, FY2025: 0.92%Net margin, FY2026: 1.18%FY2022FY2023FY2024FY2025FY2026
Gross margin FY2022 4.79%. Gross margin FY2023 4.29%. Gross margin FY2024 3.95%. Gross margin FY2025 3.48%. Gross margin FY2026 3.61%. Operating margin FY2022 1.03%. Operating margin FY2023 1.61%. Operating margin FY2024 1.27%. Operating margin FY2025 1.22%. Operating margin FY2026 1.60%. Net margin FY2022 0.42%. Net margin FY2023 1.29%. Net margin FY2024 0.97%. Net margin FY2025 0.92%. Net margin FY2026 1.18%.

Income trends

Revenue

403.43B USD+12.36%

Operating income

6.45B USD+47.62%

Net income

4.76B USD+44.52%
Income trends across reported periods443.66B USD282.74B USD121.81B USD−39.12B USDRevenue, FY2022: 263.97B USDRevenue, FY2023: 276.71B USDRevenue, FY2024: 308.95B USDRevenue, FY2025: 359.05B USDRevenue, FY2026: 403.43B USDOperating income, FY2022: 2.72B USDOperating income, FY2023: 4.45B USDOperating income, FY2024: 3.93B USDOperating income, FY2025: 4.37B USDOperating income, FY2026: 6.45B USDNet income, FY2022: 1.11B USDNet income, FY2023: 3.56B USDNet income, FY2024: 3B USDNet income, FY2025: 3.3B USDNet income, FY2026: 4.76B USDFY2022FY2023FY2024FY2025FY2026
Revenue FY2022 263.97B USD. Revenue FY2023 276.71B USD. Revenue FY2024 308.95B USD. Revenue FY2025 359.05B USD. Revenue FY2026 403.43B USD. Operating income FY2022 2.72B USD. Operating income FY2023 4.45B USD. Operating income FY2024 3.93B USD. Operating income FY2025 4.37B USD. Operating income FY2026 6.45B USD. Net income FY2022 1.11B USD. Net income FY2023 3.56B USD. Net income FY2024 3B USD. Net income FY2025 3.3B USD. Net income FY2026 4.76B USD.
Metric (USD)FY2026FY2025FY2024FY2023FY2022
Revenue403.43B USD359.05B USD308.95B USD276.71B USD263.97B USD
Cost of goods sold388.88B USD346.57B USD296.75B USD264.84B USD251.32B USD
Gross profit14.55B USD12.49B USD12.2B USD11.87B USD12.65B USD
Research and development103M USD91M USD77M USD89M USD70M USD
Selling, general, and administrative−8.1B USD8.02B USD8.2B USD7.33B USD9.86B USD
Operating expenses8.1B USD8.11B USD8.28B USD7.42B USD9.93B USD
Interest income179M USD173M USD118M USD107M USD10M USD
Interest expense247M USD256M USD243M USD248M USD178M USD
Depreciation and amortization729M USD636M USD635M USD857M USD1B USD
Operating income6.45B USD4.37B USD3.93B USD4.45B USD2.72B USD
Net income4.76B USD3.3B USD3B USD3.56B USD1.11B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+3.03%
11 comparable reports
Latest EPS result
9.93
Estimate 9.56 · Beat by 3.87%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates12.1610.639.097.56Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 8.03, estimate 8.6, surprise -6.63%, Miss. Q2 2025, reported May 8, 2025: actual 10.12, estimate 9.83, surprise +2.95%, Beat. Q3 2025, reported Aug 6, 2025: actual 8.26, estimate 8.14, surprise +1.47%, Beat. Q4 2025, reported Nov 5, 2025: actual 9.86, estimate 9.03, surprise +9.19%, Beat. Q1 2026, reported Feb 4, 2026: actual 9.34, estimate 9.17, surprise +1.85%, Beat. Q2 2026, reported May 7, 2026: actual 11.69, estimate 11.56, surprise +1.12%, Beat. Q3 2026, reported Aug 5, 2026: actual 9.93, estimate 9.56, surprise +3.87%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 10.74, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates114.32B105.02B95.72B86.43BQ1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 5, 2025: actual 95.29B USD, estimate 96.05B USD, surprise -0.79%, Miss. Q2 2025, reported May 8, 2025: actual 90.82B USD, estimate 94.3B USD, surprise -3.69%, Miss. Q3 2025, reported Aug 6, 2025: actual 97.83B USD, estimate 96.18B USD, surprise +1.71%, Beat. Q4 2025, reported Nov 5, 2025: actual 103.15B USD, estimate 104.14B USD, surprise -0.95%, Miss. Q1 2026, reported Feb 4, 2026: actual 106.16B USD, estimate 105.8B USD, surprise +0.34%, Beat. Q2 2026, reported May 7, 2026: actual 96.3B USD, estimate 101.35B USD, surprise -4.98%, Miss. Q3 2026, reported Aug 5, 2026: actual 105.38B USD, estimate 103.88B USD, surprise +1.45%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate 109.92B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

12 institutions

Corporate actions

Corporate action history

Stock split

Effective Jan 5, 1998

2:1

MCK peers

Continue in GoAI

Research MCK

research.disclaimer